Skip to main content

Guido Ferrari, MD

Associate Professor of Surgery
Associate Research Professor in Molecular Genetics and Microbiology
Office: 115 Surg Oncol Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

The activities of the Ferrari Laboratory are based on both independent basic research and immune monitoring studies. The research revolves around three main areas of interest: class I-mediated cytotoxic CD8+ T cell responses, antibody-dependent cellular cytotoxicity (ADCC), gene expression in NK and T cellular subsets upon infection with HIV-1. With continuous funding over the last 11 years from the NIH and Bill & Melinda Gates Foundation along with many other productive collaborations within and outside of Duke, the Ferrari Lab has expanded its focus of research to include the ontogeny of HIV-1 specific immune responses that work by eliminating HIV-1 infected cells and how these can be induced by AIDS vaccine candidates.

Education and Training

  • M.D., University of Genoa (Italy), 1985

Selected Grants

Publications

Hankins, Catherine A., Sinata Koulla-Shiro, Peter Kilmarx, Guido Ferrari, Mauro Schechter, Coumba Touré Kane, François Venter, et al. “Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaoundé, Cameroon.” Antivir Ther 22, no. 2 (2017): 179–84. https://doi.org/10.3851/IMP3165.

Full Text

Buchbinder, Susan P., Nicole A. Grunenberg, Brittany J. Sanchez, Kelly E. Seaton, Guido Ferrari, M Anthony Moody, Nicole Frahm, et al. “Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.” Plos One 12, no. 7 (2017): e0179597. https://doi.org/10.1371/journal.pone.0179597.

Full Text

Huang, Yunda, Guido Ferrari, Galit Alter, Donald N. Forthal, John C. Kappes, George K. Lewis, J Christopher Love, et al. “Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.” J Immunol 197, no. 12 (December 15, 2016): 4603–12. https://doi.org/10.4049/jimmunol.1601197.

Full Text

Luo, Kan, Hua-Xin Liao, Ruijun Zhang, David Easterhoff, Kevin Wiehe, Thaddeus C. Gurley, Lawrence C. Armand, et al. “Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques.” Jci Insight 1, no. 20 (December 8, 2016): e88522. https://doi.org/10.1172/jci.insight.88522.

Full Text

Ferrari, Guido, Barton F. Haynes, Scott Koenig, Jeffrey L. Nordstrom, David M. Margolis, and Georgia D. Tomaras. “Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection.” Nat Rev Drug Discov 15, no. 12 (December 2016): 823–34. https://doi.org/10.1038/nrd.2016.173.

Full Text

Astronomo, Rena D., Sampa Santra, Lamar Ballweber-Fleming, Katharine G. Westerberg, Linh Mach, Tiffany Hensley-McBain, Laura Sutherland, et al. “Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.” Ebiomedicine 14 (December 2016): 97–111. https://doi.org/10.1016/j.ebiom.2016.11.024.

Full Text

Gay, Cynthia L., Sarah J. Willis, Anna B. Cope, JoAnn D. Kuruc, Kara S. McGee, Joe Sebastian, Amanda M. Crooks, et al. “Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.” Aids 30, no. 18 (November 28, 2016): 2815–22. https://doi.org/10.1097/QAD.0000000000001255.

Full Text

Costa, Matthew R., Justin Pollara, Regina Whitney Edwards, Michael S. Seaman, Miroslaw K. Gorny, David C. Montefiori, Hua-Xin Liao, Guido Ferrari, Shan Lu, and Shixia Wang. “Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001.” J Virol 90, no. 22 (November 15, 2016): 10362–78. https://doi.org/10.1128/JVI.01458-16.

Full Text

Pages